InflaRx to Report First Quarter 2025 Results on May 7, 2025
InflaRx, a pioneering biopharmaceutical company listed on Nasdaq (IFRX), has announced it will release its first quarter 2025 financial and operating results on May 7, 2025, before market opening. No earnings call is scheduled.
The company specializes in developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathways. Their flagship product, vilobelimab, is an intravenous first-in-class anti-C5a antibody that has shown promising clinical results across multiple indications. Additionally, they are developing INF904, an oral C5a receptor inhibitor.
Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. The company operates through two wholly owned subsidiaries: InflaRx GmbH in Germany and InflaRx Pharmaceuticals in the USA.
InflaRx, un'azienda biofarmaceutica innovativa quotata al Nasdaq (IFRX), ha annunciato che pubblicherà i risultati finanziari e operativi del primo trimestre 2025 il 7 maggio 2025, prima dell'apertura del mercato. Non è prevista alcuna conference call per i risultati.
L'azienda è specializzata nello sviluppo di terapie anti-infiammatorie che agiscono sul sistema del complemento, in particolare sulle vie C5a e C5aR. Il loro prodotto di punta, vilobelimab, è un anticorpo anti-C5a per infusione endovenosa di prima classe che ha mostrato risultati clinici promettenti in diverse indicazioni. Inoltre, stanno sviluppando INF904, un inibitore orale del recettore C5a.
Fondata nel 2007, InflaRx ha sedi a Jena e Monaco di Baviera, in Germania, e ad Ann Arbor, Michigan, USA. L'azienda opera tramite due filiali interamente controllate: InflaRx GmbH in Germania e InflaRx Pharmaceuticals negli Stati Uniti.
InflaRx, una empresa biofarmacéutica pionera cotizada en el Nasdaq (IFRX), ha anunciado que publicará sus resultados financieros y operativos del primer trimestre de 2025 el 7 de mayo de 2025, antes de la apertura del mercado. No se ha programado ninguna llamada para discutir los resultados.
La compañía se especializa en el desarrollo de terapéuticas antiinflamatorias dirigidas al sistema del complemento, específicamente a las vías C5a y C5aR. Su producto estrella, vilobelimab, es un anticuerpo anti-C5a intravenoso de primera clase que ha mostrado resultados clínicos prometedores en múltiples indicaciones. Además, están desarrollando INF904, un inhibidor oral del receptor C5a.
Fundada en 2007, InflaRx tiene oficinas en Jena y Múnich, Alemania, y en Ann Arbor, Michigan, EE.UU. La empresa opera a través de dos subsidiarias de propiedad total: InflaRx GmbH en Alemania e InflaRx Pharmaceuticals en EE.UU.
InflaRx는 나스닥 (IFRX)에 상장된 선도적인 생명공학 제약회사로, 2025년 5월 7일 시장 개장 전 2025년 1분기 재무 및 운영 실적을 발표할 예정입니다. 실적 발표를 위한 컨퍼런스 콜은 예정되어 있지 않습니다.
이 회사는 보체 시스템, 특히 C5a 및 C5aR 경로를 표적으로 하는 항염증 치료제 개발에 주력하고 있습니다. 대표 제품인 빌로벨리맙(vilobelimab)은 정맥 주사 방식의 최초의 항-C5a 항체로, 여러 적응증에서 유망한 임상 결과를 보였습니다. 또한 경구용 C5a 수용체 억제제인 INF904도 개발 중입니다.
2007년에 설립된 InflaRx는 독일 예나와 뮌헨, 미국 미시간주 앤아버에 사무소를 두고 있습니다. 회사는 독일의 InflaRx GmbH와 미국의 InflaRx Pharmaceuticals 두 개의 완전 자회사로 운영되고 있습니다.
InflaRx, une entreprise biopharmaceutique innovante cotée au Nasdaq (IFRX), a annoncé qu'elle publiera ses résultats financiers et opérationnels du premier trimestre 2025 le 7 mai 2025, avant l'ouverture des marchés. Aucun appel aux résultats n'est prévu.
L'entreprise se spécialise dans le développement de thérapeutiques anti-inflammatoires ciblant le système du complément, en particulier les voies C5a et C5aR. Leur produit phare, vilobelimab, est un anticorps anti-C5a intraveineux de première classe ayant montré des résultats cliniques prometteurs dans plusieurs indications. Par ailleurs, ils développent INF904, un inhibiteur oral du récepteur C5a.
Fondée en 2007, InflaRx possède des bureaux à Jena et Munich en Allemagne, ainsi qu'à Ann Arbor dans le Michigan, aux États-Unis. La société opère via deux filiales détenues à 100 % : InflaRx GmbH en Allemagne et InflaRx Pharmaceuticals aux États-Unis.
InflaRx, ein führendes biopharmazeutisches Unternehmen, das an der Nasdaq (IFRX) notiert ist, hat angekündigt, seine Finanz- und Betriebsergebnisse für das erste Quartal 2025 am 7. Mai 2025 vor Börsenöffnung zu veröffentlichen. Eine Telefonkonferenz zur Ergebnisbesprechung ist nicht geplant.
Das Unternehmen spezialisiert sich auf die Entwicklung von entzündungshemmenden Therapeutika, die das Komplementsystem, insbesondere die C5a- und C5aR-Signalwege, gezielt angreifen. Ihr Flaggschiff-Produkt, Vilobelimab, ist ein intravenös verabreichtes, erstes Antikörperpräparat gegen C5a, das in mehreren Indikationen vielversprechende klinische Ergebnisse gezeigt hat. Zudem entwickeln sie INF904, einen oralen C5a-Rezeptor-Inhibitor.
Gegründet im Jahr 2007, unterhält InflaRx Büros in Jena und München, Deutschland, sowie in Ann Arbor, Michigan, USA. Das Unternehmen operiert über zwei vollständig im Besitz befindliche Tochtergesellschaften: InflaRx GmbH in Deutschland und InflaRx Pharmaceuticals in den USA.
- Development of two complementary drug candidates: vilobelimab (intravenous) and INF904 (oral)
- Established international presence with offices in Germany and USA
- Proprietary anti-C5a and anti-C5aR technology platform
- Multiple clinical studies showing disease-modifying activity for vilobelimab
- No earnings call scheduled, limiting investor interaction
- Forward-looking statements indicate significant risks and uncertainties
- Multiple clinical programs may increase cash burn rate
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) release Q1 2025 financial results?
What are InflaRx's main drug candidates and therapeutic focus?
Where is InflaRx (IFRX) located and operating?
How does InflaRx's (IFRX) technology platform work?
What is vilobelimab and how effective is it?
